StockData
Adlai Nortye Group Ltd. logo

Adlai Nortye Group Ltd. (ANL) stock

ANLNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 20-F on Apr 10, 2026Score 0/30
$9.48−0.55 (-5.48%)

Close on Nov 17, 2026Market cap $379.20MP/E –Yield –

Adlai Nortye r&d expenses

Research and development expenses are spending on new products and technology.

For fiscal 2025 it was $32.83M, down 26.9% from the year before. The highest annual figure on record is $58.15M in fiscal 2023.

Annual r&d expenses

PeriodPeriod endValueChange
FY2025Dec 31, 2025$32.83M-26.9%
FY2024Dec 31, 2024$44.92M-22.8%
FY2023Dec 31, 2023$58.15M+6.7%
FY2022Dec 31, 2022$54.49M+29.4%
FY2021Dec 31, 2021$42.11M–

More Adlai Nortye figures

See a number that looks wrong?